Mobile Health Technology for Atrial Fibrillation Management Integrating Decision Support, Education, and Patient Involvement: mAF App Trial.

BACKGROUND Mobile Health technology for the management of patients with atrial fibrillation is unknown. METHODS The simple mobile AF (mAF) App was designed to incorporate clinical decision-support tools (CHA2DS2-VASc [Congestive heart failure, Hypertension, Age ≥75 years, Diabetes Mellitus, Prior Stroke or TIA, Vascular disease, Age 65-74 years, Sex category], HAS-BLED [Hypertension, Abnormal renal/liver function, Stroke, Bleeding history or predisposition, Labile INR, Elderly, Drugs/alcohol concomitantly], SAMe-TT2R2 [Sex, Age <60 years, Medical history, Treatment, Tobacco use, Race] scores), educational materials, and patient involvement strategies with self-care protocols and structured follow-up. Patients with atrial fibrillation were randomized into 2 groups (mAF App vs usual care) in a cluster randomized design pilot study. Patients' knowledge, quality of life, drug adherence, and anticoagulation satisfaction were evaluated at baseline, 1 month, and 3 months. Usability, feasibility, and acceptability of the mAF App were assessed at 1 month. RESULTS A total of 113 patients were randomized to mAF App intervention (mean age, 67.4 years; 57.5% were male; mean follow-up, 69 days), and 96 patients were randomized to usual care (mean age, 70.9 years; 55.2% were male; mean follow-up, 95 days). More than 90% of patients reported that the mAF App was easy, user-friendly, helpful, and associated with significant improvements in knowledge compared with the usual care arm (P values for trend <.05). Drug adherence and anticoagulant satisfaction were significantly better with the mAF App versus usual care (all P < .05). Quality of life scores were significantly increased in the mAF App arm versus usual care, with anxiety and depression reduced (all P < .05). CONCLUSIONS The pilot mAFA Trial is the first prospective randomized trial of Mobile Health technology in patients with atrial fibrillation, demonstrating that the mAF App, integrating clinical decision support, education, and patient-involvement strategies, significantly improved knowledge, drug adherence, quality of life, and anticoagulation satisfaction.

[1]  Emily C. O'Brien,et al.  Factors associated with non–vitamin K antagonist oral anticoagulants for stroke prevention in patients with new‐onset atrial fibrillation: Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT‐AF II) , 2017, American heart journal.

[2]  F. Kamali,et al.  The value of education and self‐monitoring in the management of warfarin therapy in older patients with unstable control of anticoagulation , 2004, British journal of haematology.

[3]  B. Gorenek,et al.  Cardiac tachyarrhythmias and patient values and preferences for their management: the European Heart Rhythm Association (EHRA) consensus document endorsed by the Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), and Sociedad Latinoamericana de Estimulación Cardíaca y Electrofisi , 2015, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[4]  Josef Kautzner,et al.  Corrigendum to: 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. , 2018, European heart journal.

[5]  Hao Wang,et al.  Prevalence, incidence, and lifetime risk of atrial fibrillation in China: new insights into the global burden of atrial fibrillation. , 2015, Chest.

[6]  M. Ezekowitz,et al.  2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. , 2014, Circulation.

[7]  A. Exadaktylos,et al.  Direct new oral anticoagulants: follow-up, guidelines and bleeding complications in general practice—a survey of Swiss general internal medicine practitioners , 2016, SpringerPlus.

[8]  Sudha Seshadri,et al.  50 year trends in atrial fibrillation prevalence, incidence, risk factors, and mortality in the Framingham Heart Study: a cohort study , 2015, The Lancet.

[9]  G. Lip,et al.  Educational Intervention Improves Anticoagulation Control in Atrial Fibrillation Patients: The TREAT Randomised Trial , 2013, PloS one.

[10]  C. Chiang,et al.  Use of antithrombotics in atrial fibrillation in Africa, Europe, Asia and South America: insights from the International RealiseAF Survey. , 2014, Archives of cardiovascular diseases.

[11]  C. Murray,et al.  Worldwide Epidemiology of Atrial Fibrillation: A Global Burden of Disease 2010 Study , 2014, Circulation.

[12]  G. Lip,et al.  Decision-making interventions to stop the global atrial fibrillation-related stroke tsunami , 2017, International journal of stroke : official journal of the International Stroke Society.

[13]  G. Lip,et al.  Improved outcomes with European Society of Cardiology guideline-adherent antithrombotic treatment in high-risk patients with atrial fibrillation: a report from the EORP-AF General Pilot Registry. , 2015, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[14]  A. Camm,et al.  Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. , 2015, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[15]  G. Lip,et al.  Adherence to oral anticoagulant therapy in patients with atrial fibrillation , 2016, Thrombosis and Haemostasis.

[16]  G. Lip,et al.  Patients' experiences of atrial fibrillation and non-vitamin K antagonist oral anticoagulants (NOACs), and their educational needs: A qualitative study. , 2017, Thrombosis research.

[17]  R. Tieleman,et al.  The atrial fibrillation knowledge scale: development, validation and results. , 2013, International journal of cardiology.

[18]  C. McHorney,et al.  The Adherence Estimator: a brief, proximal screener for patient propensity to adhere to prescription medications for chronic disease. , 2009, Current medical research and opinion.

[19]  D. Levy,et al.  Lifetime Risk for Development of Atrial Fibrillation: The Framingham Heart Study , 2004, Circulation.

[20]  M. Ezekowitz,et al.  2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. , 2014, Circulation.

[21]  G. Lip,et al.  Stroke prevention in atrial fibrillation: Past, present and future , 2017, Thrombosis and Haemostasis.

[22]  Hao Wang,et al.  Time Trends of Aspirin and Warfarin Use on Stroke and Bleeding Events in Chinese Patients With New-Onset Atrial Fibrillation. , 2015, Chest.

[23]  A. Camm,et al.  Evolving antithrombotic treatment patterns for patients with newly diagnosed atrial fibrillation , 2016, Heart.

[24]  Marek Malik,et al.  e-Health: a position statement of the European Society of Cardiology. , 2016, European heart journal.

[25]  M. Janzon,et al.  Clinical decision support for stroke prevention in atrial fibrillation (CDS‐AF): Rationale and design of a cluster randomized trial in the primary care setting , 2017, American heart journal.

[26]  B. Spring,et al.  Current Science on Consumer Use of Mobile Health for Cardiovascular Disease Prevention: A Scientific Statement From the American Heart Association. , 2015, Circulation.

[27]  A. Hofman,et al.  Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study. , 2006, European heart journal.

[28]  Dylan L. Steen,et al.  Using an Atrial Fibrillation Decision Support Tool for Thromboprophylaxis in Atrial Fibrillation: Effect of Sex and Age , 2016, Journal of the American Geriatrics Society.

[29]  Ulrich Schotten,et al.  2016 ESC Guidelines for the Management of Atrial Fibrillation Developed in Collaboration With EACTS. , 2017, Revista espanola de cardiologia.

[30]  B. Bajorek,et al.  Pilot of a Computerised Antithrombotic Risk Assessment Tool Version 2 (CARATV2.0) for stroke prevention in atrial fibrillation. , 2017, Cardiology journal.

[31]  Dylan L. Steen,et al.  Impact of an Atrial Fibrillation Decision Support Tool on thromboprophylaxis for atrial fibrillation. , 2016, American heart journal.

[32]  G. Lip,et al.  The Changing Landscape for Stroke Prevention in AF: Findings From the GLORIA-AF Registry Phase 2. , 2017, Journal of the American College of Cardiology.

[33]  Gerhard Hindricks,et al.  2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation--developed with the special contribution of the European Heart Rhythm Association. , 2012, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[34]  P. Kirchhof,et al.  2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. , 2016, European heart journal.